Optic Neuropathy - Pipeline Review, H2 2015

Publisher Name :
Date: 26-Aug-2015
No. of pages: 50
Inquire Before Buying

Global Markets Direct's, ‘Optic Neuropathy - Pipeline Review, H2 2015', provides an overview of the Optic Neuropathy's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Optic Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Optic Neuropathy and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy

  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in the therapeutics development for Optic Neuropathy and enlists all their major and minor projects

  • The report summarizes all the dormant and discontinued pipeline projects

  • A review of the Optic Neuropathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • A detailed assessment of monotherapy and combination therapy pipeline projects

  • Coverage of the Optic Neuropathy pipeline on the basis of target, MoA, route of administration and molecule type

  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy

  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

  • Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Optic Neuropathy - Pipeline Review, H2 2015

Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Optic Neuropathy Overview 6
Therapeutics Development 7
Pipeline Products for Optic Neuropathy - Overview 7
Pipeline Products for Optic Neuropathy - Comparative Analysis 8
Optic Neuropathy - Therapeutics under Development by Companies 9
Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes 10
Optic Neuropathy - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Optic Neuropathy - Products under Development by Companies 13
Optic Neuropathy - Products under Investigation by Universities/Institutes 14
Optic Neuropathy - Companies Involved in Therapeutics Development 15
Inotek Pharmaceuticals Corporation 15
Neurotech Pharmaceuticals, Inc. 16
PharmatrophiX, Inc. 17
Quark Pharmaceuticals, Inc. 18
Regenera Pharma Ltd. 19
Optic Neuropathy - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
Antibody to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
BA-240 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NT-501 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
QPI-1007 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
RPh-201 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Agonize TrkB for Ophthalmology and Central Nervous System - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Synthetic Peptide to Inhibit Connexin for Optic Neuropathy - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
trabodenoson - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Optic Neuropathy - Recent Pipeline Updates 44
Optic Neuropathy - Dormant Projects 47
Optic Neuropathy - Product Development Milestones 48
Featured News & Press Releases 48
Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy 48
Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

List of Tables

Number of Products under Development for Optic Neuropathy, H2 2015 7
Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Development, H2 2015 12
Products under Development by Companies, H2 2015 13
Products under Investigation by Universities/Institutes, H2 2015 14
Optic Neuropathy - Pipeline by Inotek Pharmaceuticals Corporation, H2 2015 15
Optic Neuropathy - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2015 16
Optic Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2015 17
Optic Neuropathy - Pipeline by Quark Pharmaceuticals, Inc., H2 2015 18
Optic Neuropathy - Pipeline by Regenera Pharma Ltd., H2 2015 19
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Stage and Target, H2 2015 22
Number of Products by Stage and Mechanism of Action, H2 2015 24
Number of Products by Stage and Route of Administration, H2 2015 26
Number of Products by Stage and Molecule Type, H2 2015 28
Optic Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015 44
Optic Neuropathy - Dormant Projects, H2 2015 47

List of Figures

Number of Products under Development for Optic Neuropathy, H2 2015 7
Number of Products under Development for Optic Neuropathy - Comparative Analysis, H2 2015 8
Number of Products under Development by Companies, H2 2015 9
Number of Products under Investigation by Universities/Institutes, H2 2015 10
Comparative Analysis by Clinical Stage Development, H2 2015 11
Comparative Analysis by Early Stage Products, H2 2015 12
Assessment by Monotherapy Products, H2 2015 20
Number of Products by Top 10 Targets, H2 2015 21
Number of Products by Stage and Top 10 Targets, H2 2015 21
Number of Products by Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 23
Number of Products by Top 10 Routes of Administration, H2 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 25
Number of Products by Top 10 Molecule Types, H2 2015 27
Number of Products by Stage and Top 10 Molecule Types, H2 2015 27
  • Global Retinoblastoma Treatment Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Nov-2018        Price: US 3480 Onwards        Pages: 121
    Retina is the third-inner layer of the eye, responsible for light and color detection. Retinoblastoma is a rare type of cancer which develops in the retina, particularly in children. Scope of the Report: In terms of drugs, the retinoblastoma treatment market can be segmented into single drugs and combinatory drugs. By types, the retinoblastoma treatment market can be categorized into unilateral retinoblastoma, bilateral retinoblastoma, and neuro-ectodermal tumors retinoblas......
  • Macular Edema - Pipeline Review, H2 2018
    Published: 13-Nov-2018        Price: US 2000 Onwards        Pages: 50
    Macular Edema - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema - Pipeline Review, H2 2018, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape. Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are man......
  • Retinal Vein Occlusion - Pipeline Review, H2 2018
    Published: 13-Nov-2018        Price: US 2000 Onwards        Pages: 112
    Retinal Vein Occlusion - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinal Vein Occlusion - Pipeline Review, H2 2018, provides an overview of the Retinal Vein Occlusion (Ophthalmology) pipeline landscape. Retinal vein occlusion is a blockage in one of the veins returning blood flow from the retina. The retina is where images are converted to nerve signals. The primary symptom of reti......
  • Global Sustained Release Ocular Drug Delivery Systems Market Insights, Forecast to 2025
    Published: 13-Nov-2018        Price: US 3900 Onwards        Pages: 114
    This report studies the global market size of Sustained Release Ocular Drug Delivery Systems in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Sustained Release Ocular Drug Delivery Systems in these regions. This research report categorizes the global Sustained Release Ocular Drug Delivery Systems market by players/brands, region, type and application. This report also studies the global market ......
  • Global Contact Lens Solution Market Research Report 2018
    Published: 09-Nov-2018        Price: US 2900 Onwards        Pages: 125
    This report studies the global Contact Lens Solution market status and forecast, categorizes the global Contact Lens Solution market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - Alcon - Ciba Vision - Bausch - AMO - Cooper Vision......
  • Global Artificial Tears Market Research Report 2018
    Published: 09-Nov-2018        Price: US 2900 Onwards        Pages: 119
    This report studies the global Artificial Tears market status and forecast, categorizes the global Artificial Tears market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report - Allergan - Alcon (Novartis) - Bausch & Lomb - Abbott - Santen ......
  • Global Juvenile Macular Degeneration Treatment Market Data Survey Report 2025
    Published: 03-Nov-2018        Price: US 1500 Onwards        Pages: 81
    Summary The global Juvenile Macular Degeneration Treatment market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufactur......
  • Global Ophthalmology Amniotic Membrane Market Data Survey Report 2025
    Published: 31-Oct-2018        Price: US 1500 Onwards        Pages: 70
    Summary The global Ophthalmology Amniotic Membrane market will reach Volume Million USD in 2018 with CAGR xx% 2018-2025. The main contents of the report including: Global market size and forecast Regional market size, production data and export & import Key manufacturers (manufacturing sites, capacity and production, product specifications etc.) Major Application Major Type Key manufacturers are included based on manufacturing sites, capacity and ......
  • Global Dry Eye Syndrome Drugs Market Size, Status and Forecast 2018-2025
    Published: 25-Oct-2018        Price: US 3900 Onwards        Pages: 98
    This report focuses on the global Dry Eye Syndrome Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Dry Eye Syndrome Drugs development in United States, Europe and China. In 2017, the global Dry Eye Syndrome Drugs market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. The key players covered in this study - Allergan - ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs